Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?
Trojano
Maria
M
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015982:Bias; D002985:Clinical Protocols / Q000592:standards; D015331:Cohort Studies; D003627:Data Interpretation, Statistical; D019992:Databases as Topic / Q000592:standards* / Q000706:statistics & numerical data; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology*; D016032:Randomized Controlled Trials as Topic / Q000592:standards* / Q000706:statistics & numerical data; D012008:Recurrence; D015203:Reproducibility of Results; D013995:Time; D016896:Treatment Outcome
D018501:Antirheumatic Agents